Correlations of leukemia inhibitory factor and macrophage migration inhibitory factor with endometrial carcinoma

Objective: To investigate the correlations of leukemia inhibitory factor (LIF) and macrophage migration inhibitory factor (MIF) with endometrial carcinoma. Materials and Methods: The study included 113 endometrial specimens from the Fourth Affiliated Hospital of Harbin Medical University, collected from May 2006 to October 2008, classified into normal endometrium, simple hyperplasia, complex hyperplasia, atypical hyperplasia, and endometrial carcinoma. The LIF and MIF expression of all 113 specimens was detected with immunohistochemistrical (IHC) method. Results: The MIF expression in hyperplastic endometrium and endometrial carcinoma increased significantly as compared with that in normal endometrium (p < 0.05 and p < 0.001, respectively), and its expression in endometrial carcinoma was also remarkably higher than that in hyperplastic endometrium (p < 0.001). The expressions of LIF in atypical hyperplasia and endometrial carcinoma were also significantly higher than that in the normal endometrium (p < 0.05), but it is not obviously higher in simple hyperplasia and complex hyperplasia than in the normal endometrium (p > 0.05). Furthermore, the expression of LIF showed no statistical difference between hyperplastic endometrium and endometrial carcinoma. Conclusion: It could be speculated that MIF may be correlated with the occurrence of endometrial carcinoma. However, whether LIF also has a correlation with the occurrence of endometrial carcinoma still cannot be presumed.

Endometrial carcinoma; LIF; MIF.

[1] Hagemann T., Robinson S.C., Thompson R.G., Charles K., Kulbe H., Balkwill F.R.: “Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth progression and angiogenesis”. Mol. Cancer Ther., 2007, 6, 1993.

[2] Mutter G.L.: “Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group”. Gynecol. Oncol., 2000, 76, 287.

[3] Tsudo T., Harada T., Iwabe T., Tanikawa M., Nagano Y., Ito M., et al.: “Altered gene expression and secretion of interleukin-6 in stromal cells derived from endometriotic tissues”. Fertil. Steril., 2000, 73, 205.

[4] Piccinni M.P.: “T cells in normal pregnancy and recurrent pregnancy loss”. Reprod. Biomed. Online, 2006, 13, 840.

[5] Cameron S.T., Critchley H.O., Buckley C.H., Kelly R.W., Baird D.T.: “Effect of two antiprogestins (mifepristone and on apristone) on endometrial factors of potential importance for implantation”. Fertil. Steril., 2007, 67, 1046.

[6] Dabbous M.K., North S.M., Haney L., Tipton D.A., Nicolson G.L.: “Effects of mast cell-macrophage interactions on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts”. Clin. Exp. Metastasis, 1995, 13, 33. [7] Patel A.V., Feiqelson H.S., Talbot J.T., McCullough M.L., Rodriguez C., Patel R.C., et al.: “The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women”. Int. J. Cancer, 2008, 123, 1877.

[8] Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K., et al.: “Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer”. J. Clin. Oncol., 2005, 23, 7919.

[9] Agarnal R., Whang D.H., Alvero A.B., Visintin I., Lai Y., Segal E.A., et al.: “Macrophage migration inhibitory factor expression in ovarian cancer”. Am. J. Obstet. Gynecol., 2007, 196, 348.e1.

[10] Danforth K.N., Tworoger S.S., Hecht J.L., Rosner B.A., Colditz G.A., Hankinson S.E.: “Breastfeeding and risk of ovarian cancer in two prospective cohorts”. Cancer Causes Control, 2007, 18, 517. Epub 2007 Apr 21.

[11] Wright T.C. Jr., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D.: “2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ”. Am. J. Obstet. Gynecol., 2007, 197, 340.

[12] Mahutte N.G., Matalliotakis L.M., Goumenou A.G., Koumantakis G.E., Vassiliadis S., Arici A.: “Elevations in peritoneal fluid macrophage migration inhibitory factor are independent of the depth of invasion or stage of endometriosis”. Fertil. Steril., 2004, 82, 97.

[13] Ohkawara T., Takeda H., Miyashita K., Nishiwaki M., Nakayama T., Taniguchi M., et al.: “Regulation of Toll-like receptor 4 expression in mouse colon by macrophage migration inhibitory factor”. Histochem. Cell. Biol., 2006, 125, 575.

[14] Xia X.A., He C.Z., Li L.H., Lu P., Pu H., Ren D.J., et al.: “Expression of macrophage migration inhibitory factor is associated with gynecologic malignant tumor”. Obstet. Gynecol., 2006, 36, 9. [15] Beaulieu E., Green L., Elsby L., Alourfi Z., Morand E.F., Ray D.W., et al.: “Identification of a novel cell type - specific intronic enhancer of macrophage migration inhibitory factor (MIF) and its regulation by mithramycin”. Clin. Exp. Immunol., 2010, 163, 178.

[16] Sakamoto W., Nishihira J., Fujie K., Iizuka T., Handa H., Ozaki M., et al.: “Effect of vitamin E on production of macrophage migration inhibitory factor (MIF) by macrophages”. Biofactors, 1999, 10, 139.

[17] Lobanok E.S., Mezhevikina L.M., Belianovich L.M., Petrova R.R., Vasilevich I.B., Volotkovski- I.D., et al.: “The influence of LIF (Leukemia Inhibitory Factor) on the functional status of R1 mouse embryonic stem cells”. Biomed. Khim., 2009, 54, 570.

[18] Albrecht S., Schols H.A., van den Heuvel E.G., Voragen A.G., Gruppen H.: “CE - LIF - MSn profiling of oligosaccharides in human milk and feces of breast - fed babies”. Electrophoresis, 2010, 31, 1264. [19] Rodat A., Couderc B., Feurer B., Couderc F.: “A new evaluation technique for the detection of impurities in purified proteins via CE with native UV - LIF”. Electrophoresis, 2010, 31, 396.

[20] Levy C.S., Slomiansky V., Gattelli A., Nahmod K., Pelisch F., Blaustein M., et al.: “Tumor necrosis factor alpha induces LIF expression through ERK1/2 activation in mammary epithelial cells”. J. Cell. Biochem., 2010, 110, 857.